

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Sativa Wellness Group Inc. (the "Issuer").

Trading Symbol: SWEL

Number of Outstanding Listed Securities: 364,615,913

Date: August 31, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company announced its first quarterly profit in Q2 2021. The Company has filed the Financial Statements and Management's Discussion and Analysis for Q2 June 2021 with exceptionally strong results which demonstrates the continued growth.

The Company exceeded all targets set to meet its ambition of diversifying within the Wellness sector through the rollout of additional COVID testing clinics and as at the date of this announcement, the Company has 57 clinics in operation. The Company is actively looking at different tests to expand the clinic portfolio and opportunities to grow the testing business.

The Company has been pursuing growth opportunities in the CBD arena while continuing to produce quality isolate and distillate in Poland and a range of quality end products through its 'Goodbody' brand in the UK.

The UK Government Chemist team has published a report summarising the findings of a ring trial to assess laboratories performance in measuring CBD and controlled cannabinoids. 32 national and international laboratories participated in the ring trial. The Company reported that, based on the average reported scores PhytoVista, the Sativa Wellness Group ISO accredited laboratory, ranked 2nd out of 32 UK and international laboratories.

2. Provide a general overview and discussion of the activities of management.

None to report

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Company announced that it has signed a distribution agreement with German partners Lexamed GMBH ("Lexamed"). This exclusive agreement will allow both parties to work together to build the Goodbody CBD brand within Germany with plans to expand this to other European countries in the future. The German market has a strong CBD market, and this is a great opportunity for both companies. The existing Goodbody range will be offered through a number of channels in Germany

FORM 7 – MONTHLY PROGRESS REPORT

October 2020
Page 2

and the companies will also work together to develop new products for the European market in conjunction with Sativa Wellness's polish extraction and manufacturing facility.

Sativa Group Limited and Lexamed shared ownership of a joint venture company Sativa GMBH. As part of this agreement the Company will transfer full ownership of Sativa GMBH to Lexamed and Sativa GMBH will be renamed as Lexalife GMBH ("Lexalife"). Lexalife will act as the distribution partner in Germany for Goodbody Botanicals Limited, Sativa's CBD production and distribution subsidiary.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to Report.

8. Describe the acquisition of new customers or loss of customers.

None to Report.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to Report.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None to Report.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report

FORM 7 – MONTHLY PROGRESS REPORT

13. Provide details of any securities issued and options or warrants granted.
None to report
14. Provide details of any loans to or by Related Persons.
None to report
15. Provide details of any changes in directors, officers or committee members.
None to report
16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None to report


Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 5, 2021.

Anne Tew
Name of Director or Senior Officer


Signature

CFO / Corporate Secretary
Official Capacity

Issuer Details Name of Issuer	For Month End August 2021	Date of Report 08/31/21
---	------------------------------	----------------------------

FORM 7 – MONTHLY PROGRESS REPORT

Sativa Wellness Group Inc.		
Issuer Address Suite 409 – 221 503-905 Pender St. W. Esplanade,		
City/Province/Postal Code Vancouver/BC/V7M 3J3	Issuer Fax No. ()	Issuer Telephone No. ()
Contact Name Anne Tew	Contact Position Corporate Secretary	Contact Telephone No. +44 (0) 13 7348 2482
Contact Email Address anne@sativawellnessgroup.com	Web Site Address www.sativawellnessgroup.com	

FORM 7 – MONTHLY PROGRESS REPORT

